In a meta-analysis of 19 studies involving 911 patients, IGB therapy reduced NAFLD activity score by a mean of 3.0 points (95% CI: –2.41 to –3.59), ALT by 10.4 U/L (95% CI: –7.31 to –13.49), liver volume by 397.9 mL (95% CI: –212.78 to –1008.58), and liver steatosis by 37.8 dB/m (95% CI: –21.59 to –53.92). The gene discussed is GPT; the disease is fatty liver disease.